Hofseth BioCare ASA reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was NOK 29.79 million compared to NOK 13.66 million a year ago. Revenue was NOK 30.22 million compared to NOK 13.66 million a year ago. Net loss was NOK 35.07 million compared to NOK 37.79 million a year ago. Basic loss per share from continuing operations was NOK 0.09 compared to NOK 0.11 a year ago. Diluted loss per share from continuing operations was NOK 0.09 compared to NOK 0.11 a year ago.
For the nine months, sales was NOK 85.28 million compared to NOK 61.43 million a year ago. Revenue was NOK 86.84 million compared to NOK 61.54 million a year ago. Net loss was NOK 99.12 million compared to NOK 89.27 million a year ago. Basic loss per share from continuing operations was NOK 0.27 compared to NOK 0.25 a year ago. Diluted loss per share from continuing operations was NOK 0.27 compared to NOK 0.25 a year ago.